Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, B-Cell 1Bronchiolitis Obliterans Syndrome 1

Interventions

fludarabine 1Whole-Body Irradiation 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, B-Cell × Dasatinib × Clear all
NCT03564470 2022-07-01

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡